Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)

• Status: Recruiting
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: All

Summary

Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis supplying the drug to close contacts of confirmed cases.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ministry of Public Health, Argentina
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Over 18 years either sex

• Women of childbearing age with a negative pregnancy test

• In close contact group or epidemiological nexus of a positive COVID-19 case

• Able to understand and grant informed consent

• Real-time - polymerase chain reaction test with a negative result

Exclusion Criteria:

• Known hypersensitivity or allergy to any component of the drug under evaluation

• Age under 18 years

• Use of immunosuppressants (including systemic corticosteroids) in the last 30 days

• Pregnant or lactating

• Patients with other acute infectious diseases

• Patients with autoimmune disease and/or chronic decompensated diseases

• Who have received a vaccine for COVID-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another COVID-19 prophylaxis study